Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Wednesday, April 24, 2019 · 483,092,846 Articles · 3+ Million Readers

China's Irbesartan Market Report, 2018-2022: Sales Value of Irbesartan on the Rise After it Entered China, Exceeding CNY 300 Million in 2017

/EIN News/ -- Dublin, Jan. 09, 2019 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Irbesartan Market, 2018-2022" report has been added to's offering.

Sartans are antihypertensive drugs with highly selective, effective and long-lasting multi-organ targeted protection. With a more specific mechanism of action, they prevent dry cough and other side effects that may be caused by angiotensin-converting enzyme inhibitors (ACEIs), and thus have replaced the ACEIs in some clinical uses.

As a result, the growth of the ACEI market slows down, which leading to a steady increase in the Sartans market. Another growth driver is the new edition of List of Medicines Covered by National Basic Medical Insurance that included compound preparations.

Irbesartan was developed by Sanofi, first approved by the European Medicines Agency (EMA) on Aug. 27, 1997, and then approved by the U.S. Food and Drug Administration (FDA) on Sept. 30, 1997. The trade name of Sanofi's Irbesartan is Aprovel. Irbesartan is mainly used to treat primary hypertension and has little effect on heart rate. Irbesartan can also protect kidneys and slow the progression of diabetic nephropathy. It can slow the progression of kidney disease for patients with both type 2 diabetic nephropathy and hypertension.

According to the researcher, domestic enterprises developed the generic versions of Aprovel early. The generic drugs were approved to be sold in China in 2000. By Sept. 2018, there are 11 Irbesartan API manufacturers, and 24 manufacturers of Irbesartan tablets, capsules and dispersible tablets in China. The Irbesartan products of Sanofi and its subsidiary Sanofi (Hangzhou) Pharmaceutical Co., Ltd. have an absolute advantage in China, taking up approximately 80% market share by sales value in 2017.

There were about 330 million hypertensive patients in China at the end of 2017. One in every three adults has high blood pressure. Chinese hypertensive patients account for about one-third of the global total. The incidence of hypertension in China rose by 32.1% from 5.1% in 1959 to 37.2% in 2017.

The sales value of Irbesartan was on the rise after it entered China, exceeding CNY 300 million in 2017. It is expected that the market size will continue to grow from 2018 to 2022 with the increasing number of hypertensive patients.

Key Topics Covered:

1 Relevant Concepts of Irbesartan
1.1 Indications for Irbesartan
1.2 Development History of Irbesartan in China
1.3 Governmental Approval of Irbesartan in China

2 Sales of Irbesartan in China, 2013-2017
2.1 Sales Value
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Irbesartan by Dosage Form in China, 2013-2017
2.3.1 Tablets
2.3.2 Capsules

3 Analysis on Major Competitors on China's Irbesartan Market, 2013-2017
3.1 Analysis on Market Share of Major Irbesartan Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Sanofi (Hangzhou) Pharmaceutical Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Sanofi (Hangzhou) Pharmaceutical Co., Ltd.'s Irbesartan in China
3.3 Sanofi
3.3.1 Enterprise Profile
3.3.2 Sales of Sanofi's Irbesartan in China
3.4 Jiangsu Hengrui Medicine Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Jiangsu Hengrui Medicine Co., Ltd.'s Irbesartan in China
3.5 Zhuhai Rundu Pharmaceutical Co., Ltd.
3.6 Weifang Zhongshi Pharmaceutical Co., Ltd.

4 Prices of Irbesartan in China, 2017-2018
4.1 Sanofi (Hangzhou) Pharmaceutical Co., Ltd. (Aprovel)
4.2 Sanofi (Aprovel)
4.3 Jiangsu Hengrui Medicine Co., Ltd. (Jijia)
4.4 Zhuhai Rundu Pharmaceutical Co., Ltd. (Yitaiqing)
4.5 Weifang Zhongshi Pharmaceutical Co., Ltd. (Bida)

5 Prospect of China's Irbesartan Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                             Laura Wood, Senior Press Manager
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Cardiovascular Drugs 


Powered by EIN News

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release